摘要
目的多西紫杉醇在局部晚期鼻咽癌奈达铂同期放化疗中联合使用的临床疗效。方法随机选择我院2012年8月~2017年9月78例局部鼻咽癌晚期的患者进行研究,将其分为两组进行治疗,随机数字表法分为治疗组和对照组,治疗组给予多西紫杉醇联合奈达铂同期放化疗,对照组给予奈达铂同期放化疗,对治疗后的CR评价、生存时间和不良反应的发生率进行分析。结果相比于对照组,治疗组的CR评价率较高,5年无肿瘤生存时间明显延长,差异有统计学意义(P<0.05);不良反应治疗组较对照组增多,但差异无统计学意义(P>0.05)。结论局部晚期鼻咽癌严重威胁患者的生命,给予多西紫杉醇联合奈达铂同期放化疗可以显著提高其治疗效果,可以显著延长患者5年生存时间,能够控制癌细胞的增长,效果显著,值得临床推广。
Objective To observe the clinical efficacy of docetaxel combined with nedaplatin concurrent chemotherapy in locally advanced nasopharyngeal carcinoma.Methods From August 2012 to September 2017,78 cases of local nasopharyngeal carcinoma in our hospital were randomly selected and divided into two groups for treatment according randomized digital tables.The patients in treatment group were given docetaxel combined with nedaplatin concurrent chemoradiotherapy.The patients in control group were given nedaplatin concurrent chemoradiotherapy.The CR evaluation,survival time after treatment and adverse reactions were analyzed.Results Compared with the control group,the CR rate in the treatment group was higher than that in the control group,and the tumor free survival time in 5 years was significantly longer than that in the control group,(P<0.05).The adverse reactions in the treatment group increased compared with the control group,but there was no significant difference between them(P>0.05).Conclusion Locally advanced nasopharyngeal carcinoma is a serious threat to the life of patients.The concurrent chemotherapy of docetaxel and nedaplatin can significantly improve the therapeutic effect,prolong the 5 year survival time of the patients and control the growth of cancer cells,and it is worthy of clinical promotion.
作者
詹德超
陈梓宏
温继育
陈晓文
ZHAN Dechao;CHEN Zihong;WEN Jiyu;CHEN Xiaowen(The Second Region of Tumor Center,Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,China)
出处
《中国医药科学》
2018年第6期198-200,共3页
China Medicine And Pharmacy
关键词
多西紫杉醇
局部晚期鼻咽癌
同期放化疗
临床效果
Docetaxel
Locally advanced nasopharyngeal carcinoma
Concurrent chemoradiotherapy
Clinical efficacy
